GenSpera CEO to Present at New York Society of Sec
Post# of 94265
Posted On: 10/28/2013 8:13:40 AM
GenSpera CEO to Present at New York Society of Security Analysts’ Life Sciences Conference
GenSpera, Inc. (OTCQB:GNSZ) announced that CEO, Craig Dionne, PhD, will present at the New York Society of Security Analysts’ Life Sciences Conference on Oct 30th, at 10:45 am, in New York, NY (http://www.nyssa.org/programs/conferencesseminars/ctl/viewdetail/mid/754/itemid/867/d/20131030.aspx). Dr. Dionne will give an overview of the company and its lead drug candidate, G-202. The company reported data from the G-202 Phase I trial in solid-tumor cancers last week.
About GenSpera
GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA which is found at high levels in liver and prostate cancer and in the vasculature of almost all other solid tumors and is therefore expected to have efficacy in a wide variety of tumor types.
Data from the G-202 Phase Ib program in solid tumor patients demonstrated that G-202 is well-tolerated with prolonged disease stabilization observed in several hepatocellular carcinoma (liver cancer) patients whose disease had previously worsened on standard therapy. A Phase II clinical trial in patients with hepatocellular carcinoma is currently underway.
For more information, please visit the Company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of GenSpera’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.
Company:
GenSpera, Inc.
Craig Dionne, PhD, 210-479-8112
CEO
or
Media:
Planet Communications
Deanne Eagle, 917-837-5866
or
Investors:
BPC Financial Marketing
John Baldissera, 800-368-1217p
GenSpera, Inc. (OTCQB:GNSZ) announced that CEO, Craig Dionne, PhD, will present at the New York Society of Security Analysts’ Life Sciences Conference on Oct 30th, at 10:45 am, in New York, NY (http://www.nyssa.org/programs/conferencesseminars/ctl/viewdetail/mid/754/itemid/867/d/20131030.aspx). Dr. Dionne will give an overview of the company and its lead drug candidate, G-202. The company reported data from the G-202 Phase I trial in solid-tumor cancers last week.
About GenSpera
GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera’s lead drug candidate, G-202, is activated by the enzyme PSMA which is found at high levels in liver and prostate cancer and in the vasculature of almost all other solid tumors and is therefore expected to have efficacy in a wide variety of tumor types.
Data from the G-202 Phase Ib program in solid tumor patients demonstrated that G-202 is well-tolerated with prolonged disease stabilization observed in several hepatocellular carcinoma (liver cancer) patients whose disease had previously worsened on standard therapy. A Phase II clinical trial in patients with hepatocellular carcinoma is currently underway.
For more information, please visit the Company’s website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of GenSpera’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.
Company:
GenSpera, Inc.
Craig Dionne, PhD, 210-479-8112
CEO
or
Media:
Planet Communications
Deanne Eagle, 917-837-5866
or
Investors:
BPC Financial Marketing
John Baldissera, 800-368-1217p
(0)
(0)